Drug makers betting on new combination products to tackle difficulties

Generic manufacturing has long been a major source of revenue for most Korean pharmaceutical firms. That heavy reliance and their weak overseas presence caused them to shirk from drug development as it costs huge amounts of time and money with no assurance of success.

Reckoning the need for long-term growth strategies, however, a surging number of companies are stepping up efforts to reinfo...